Anny-Odile Colson

Title: Anny-Odile Colson: Innovator in CRF Receptor Antagonists

Introduction

Anny-Odile Colson is a prominent inventor based in Horsham, GB. She has made significant contributions to the field of pharmacology, particularly in the development of compounds that target corticotropin releasing factor (CRF) receptors. With a total of 2 patents to her name, Colson's work is paving the way for advancements in therapeutic interventions.

Latest Patents

Colson's latest patents include innovative cyclohexyl amide derivatives that serve as CRF receptor antagonists. These compounds are described in detail in her patents, highlighting their potential utility in treating conditions related to CRF receptor activity. The formulations are aimed at providing new avenues for therapeutic applications.

Career Highlights

Anny-Odile Colson is currently associated with Novartis AG, a leading global healthcare company. Her role at Novartis has allowed her to focus on research and development in the field of organic compounds, particularly those that can influence CRF receptor functions. Her expertise and dedication have positioned her as a key player in her area of research.

Collaborations

Throughout her career, Colson has collaborated with notable colleagues, including David Beattie and Andrew James Culshaw. These collaborations have fostered a productive environment for innovation and have contributed to the successful development of her patented compounds.

Conclusion

Anny-Odile Colson's work in the field of CRF receptor antagonists exemplifies her commitment to advancing medical science. Her contributions through her patents and collaborations continue to impact the pharmaceutical landscape positively.